{"name":"TILT Biotherapeutics Ltd.","slug":"tilt-biotherapeutics-ltd","ticker":"","exchange":"","domain":"tiltbiotherapeutics.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxOUXNBbUZoNWZQMTlDdmxWZHd1djNpVm93TWhYSDNrRDRXbWRqZmFGR2ZLSWZ2d1J2a1E1QnJjbkJTc1hqS0NnYlZfbnFETGJDR0Y0VFBKV1h2dEFneW9BTTZGVHpZTkF6dl92Zi1BanZMeUNTNkpPZF9kaFBQT0tpcGRaWDBNeXQ1QUx5MFVJdG9wbFJzZ1hBeGdVbTN1bWFBWHktWTNBU2lRclJUMGxCLVdSZmtOaDIxZWdBMzk0OEo1VUgzTndYNk9xejducXk0TkotZ280ZXRTcy0tX0h2OVhFUTRSbm41ZmZsdEthVmJBOVJFX1E?oc=5","date":"2026-04-02","type":"trial","source":"Barchart.com","summary":"Melanoma Clinical Trial Pipeline Gains Momentum: 150+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com","headline":"Melanoma Clinical Trial Pipeline Gains Momentum: 150+ Companies Lead the Charge in Pioneering New Treatments | DelveInsi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxQT195Um84VEw5TDFnZ0x5N0VydUJ0aDNTVGF1SDVWdjh0bEFwbEtyZzM4R2ZEbENDdTVwQzJSV0ZrUU9JSlVZbTZ5TXlYd3NyYmpXT3pVMzdEUHRuTi1lYURucmpkR2M4bzJTeTFNU05iM3dIX0JNNzdoT1otUWVoT3VZamZrTzA5bmYxaUxmTEMxZVpuWm5aRFlVdmZWeXRxU2lWclBRLXg0eEZndGl6VkxBUGRYWjFHdHp0bU9jdnQ1SmpfLXlOd3dPTkhSMTJPRHdDZlpfMjdHQjNyR21Zd2pnU21aQTNOam1SZUw5ZkNyb19xOUMyc0pxRnl4Z2hnRHdLc19CTkdQSy1EYTdDTFRuYkZYRHE0S2tFYm1TMVI?oc=5","date":"2025-10-14","type":"trial","source":"GlobeNewswire","summary":"Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma - GlobeNewswire","headline":"Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE9JaENCMmhVQW1YcWNRNXQzTnpHcDkxdTNvWG5vaFI1VUpSVE1wMnIzNkJYWThCcjcwWC1PS0F5TFR0OGRQUDJPOWRLdlNfd1NlaTdoR096RnE2czBfNllUYjBTcE02MGgxSVAtX2R0RGpwQQ?oc=5","date":"2025-05-23","type":"pipeline","source":"labiotech.eu","summary":"Finland’s biotech stars: 9 names you will want to remember - labiotech.eu","headline":"Finland’s biotech stars: 9 names you will want to remember","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQVEgzV09OcHZ5Q3ZDTDNtOUZTMl9EQlJnTnhXR1hVMElHZXQ5MXhBMjhyVFE1QzhQeWxrN1E0MnAwYlV4WUQtNHd6V3RMWmMyZG15LVY4YmpaZjB1Qklld2pKSlpaWkt1RmZDQjFVNTE0aTQyZ0lEMHI5dGlNM3Z5U0V1aElQYnpYQzFn?oc=5","date":"2025-05-16","type":"pipeline","source":"pharmaphorum","summary":"Pathos AI's big $365m Series D, and other bio financings - pharmaphorum","headline":"Pathos AI's big $365m Series D, and other bio financings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOVW55YXJrQjdLR3lfLUJYTkpDR0NzX1ZaR2d1REo5SV9OWkVSSmQtN09rTDFmeXAwaDBRSkdnN29vSk1MZzJUT0JkbXN3dkZ5cE1tVWFLQUV3S2N2bEd0ZHU5U3JIZm95cDRpa2ozWHpDZmhGdTZ2SEQxSWd1czJXOE1RZlZXRlpYc0FQdEgwTk5pM1dzYXlrbWJCNkVVdTNOVlFYM21PQjA4UTQxWkdRZjk1NGhieHFUaUQydEdZRTlHcFNvbXhodHlHNjhWUTI2RjZtMnRZZkxGMnp6ZWs5eA?oc=5","date":"2025-05-13","type":"pipeline","source":"GlobeNewswire","summary":"TILT Biotherapeutics Announces Closing of USD 25 Million Series B Financing - GlobeNewswire","headline":"TILT Biotherapeutics Announces Closing of USD 25 Million Series B Financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxQV1JBcWNmYk85cFJyVU9PYzE1c0x3b2RjcW9fN1JUQ1FNc1BRUjNMRkltMTl3cHZCdnpoOHFvQlFCY3BrQ0ZWa1lxQnNCb055NlZyVlcwelZGd1hxRmhCVnBybXdSS1B3eFJZT1JUV0JfWGFEM2Vvc3ZJNzdRdUlPcmR4YkJjSEEyWGhIYm0xZkk0cXJLTzNXeXR3anY5cjA4eEQwbzNVWjUtSWxDdm55Ti0zWFh3TW8zUnlRcmpVTFhQc0NCMmJydTdVUzBYbXdGbGR5R2xPeWNLX3VuV0t6bWduNW1GYnhSYl8zbmFfa2lteDBGTzNtQUlKNHlOczZjYXFISHdpc3dtUm9IY0FCNmQwZ2hPeEhYdTAwaFFwTXlGd2Z4NHdpbUxiZXU1dGM5UjBrVjQ2UTc5QlJkM0NyUVlQWnBQTkU?oc=5","date":"2025-03-05","type":"trial","source":"GlobeNewswire","summary":"CAR T-cell Therapy Clinical Trial Pipeline Experiences - GlobeNewswire","headline":"CAR T-cell Therapy Clinical Trial Pipeline Experiences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1hQUpZVll0SDBhOGFfTWtsV1p3V3NjZ1VpVzZRVGZGWVdsLVIwWmo0WlRDbHFXeUZvZ2ZWMm14dVFDekY5N1RqNlBGUjNJTWs0Q29xRnF4Y1JpRE53VWlz?oc=5","date":"2025-02-05","type":"trial","source":"nature.com","summary":"The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial - nature.com","headline":"The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PR","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxQOG1CekNpZ1duWUg3aVRzWG0zVFdnTmdTb3hHRVVxSHdsZzJmVDk1VnhSWVBES2NuWjFSdXl5OUI3azZMUFkwdUZ6S1hZMmZibVdLTFBpcHRRUG93SDBJVnFSbXRVdlBqVkEtWVFfM0ZfTFJCTkdpZzhKaFlGcEhPM1BnUFk4WE53c1BqSkhoa1F3WTJ3QjM4VmthVHhsWFVfRXlvbnc5RUEzWWtQaHVXTHAxNl9fOG1hcG03bjNtZXg0NXQtTnF4dXk4TkpkMC1lOU1xTy1RbzdtMGhHRkZTRmZIS0pYMXdVcmhjYk95ODZzZWdzYXc?oc=5","date":"2024-10-08","type":"pipeline","source":"PR Newswire","summary":"CD47 Inhibitors Market Projected to Grow Significantly with Emerging Cancer Therapies by 2034 | DelveInsight - PR Newswire","headline":"CD47 Inhibitors Market Projected to Grow Significantly with Emerging Cancer Therapies by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxPYV9VNFJsdUZhM19wVzhRYUxlbjlELUZXeHMwQjRMMUVaWGhndTdsdm13SGd2bXZFZ25QZXpURWhhT1QyU3Z4b0dLNkp3eXVRQlFGZkZqLXVXRFZQZ19idm8wMndYaEwxWUhiYWdMZklXejlrQWFhd2hZVmIxVE11S1pTRnVXM25ldDNNT29wcE1EWm1OTUUwUnA3YzdmY0VITFNJTEMzcHM1bm9SUENXTENsY0lpQm9QNlBmYVVXRmFxOHJ0eTEtanphUDZGU0hiYzdJZEtUUTF1T1Q0TFBWRUFwNC04SVBoSTJGNFBYN0tRV1FWV3ZCWjNyNmlQNE1lQngxamRyaEN0TVdmT19heW5oR3NLc0RFcl9Z?oc=5","date":"2023-02-07","type":"trial","source":"businesswire.com","summary":"TILT Biotherapeutics Announces Final Close of €22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials - businesswire.com","headline":"TILT Biotherapeutics Announces Final Close of €22 Million Financing Round to Advance to Phase II Oncology Immunotherapy ","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}